JP2014533681A5 - - Google Patents

Download PDF

Info

Publication number
JP2014533681A5
JP2014533681A5 JP2014541807A JP2014541807A JP2014533681A5 JP 2014533681 A5 JP2014533681 A5 JP 2014533681A5 JP 2014541807 A JP2014541807 A JP 2014541807A JP 2014541807 A JP2014541807 A JP 2014541807A JP 2014533681 A5 JP2014533681 A5 JP 2014533681A5
Authority
JP
Japan
Prior art keywords
peptide
seq
set forth
sequence set
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014541807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533681A (ja
JP6426001B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/056533 external-priority patent/WO2013072901A2/en
Publication of JP2014533681A publication Critical patent/JP2014533681A/ja
Publication of JP2014533681A5 publication Critical patent/JP2014533681A5/ja
Application granted granted Critical
Publication of JP6426001B2 publication Critical patent/JP6426001B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014541807A 2011-11-17 2012-11-18 神経膠腫を治療するための組成物および方法 Expired - Fee Related JP6426001B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161561080P 2011-11-17 2011-11-17
US61/561,080 2011-11-17
US201261583745P 2012-01-06 2012-01-06
US61/583,745 2012-01-06
PCT/IB2012/056533 WO2013072901A2 (en) 2011-11-17 2012-11-18 Compositions and methods for treating glioma

Publications (3)

Publication Number Publication Date
JP2014533681A JP2014533681A (ja) 2014-12-15
JP2014533681A5 true JP2014533681A5 (https=) 2016-01-14
JP6426001B2 JP6426001B2 (ja) 2018-11-21

Family

ID=47358252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541807A Expired - Fee Related JP6426001B2 (ja) 2011-11-17 2012-11-18 神経膠腫を治療するための組成物および方法

Country Status (7)

Country Link
US (2) US9453050B2 (https=)
EP (1) EP2780363B1 (https=)
JP (1) JP6426001B2 (https=)
KR (1) KR20140103122A (https=)
CA (1) CA2856329A1 (https=)
IL (1) IL232648B (https=)
WO (1) WO2013072901A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
CA2962757C (en) * 2014-09-26 2022-03-22 National University Of Singapore Methods and compositions for modulating th-gm cell function
US11078264B2 (en) * 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
US12582695B2 (en) * 2018-11-28 2026-03-24 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Compositions and methods for treating glioma
CN112007142B (zh) * 2019-05-31 2025-04-22 生物蚕茧研究所股份有限公司 向抗炎m2表型小胶质细胞的极性转化促进剂
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102899196B1 (ko) * 2023-01-20 2025-12-12 (주) 넥셀 치주염 및 임플란트 주변염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 치주염 및 임플란트 주변염 예방 또는 치료용 조성물
CN116650650A (zh) * 2023-06-12 2023-08-29 郑州大学 一种抑制食管鳞癌中肿瘤相关巨噬细胞浸润的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0482086A1 (en) * 1989-07-14 1992-04-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
EP0486572B1 (en) * 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
AU756916B2 (en) 1998-11-12 2003-01-23 Jcr Pharmaceuticals Co., Ltd. Modulation of cell proliferative disorders by cyclic RGD
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
AU2592600A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
ATE507295T1 (de) * 2000-03-30 2011-05-15 Dendreon Corp Zusammensetzungen und verfahren für eine auf dendritischen zellen basierende immuntherapie
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002323151A1 (en) 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AU2003276828A1 (en) * 2002-05-10 2004-03-11 Children's Medical Center Corporation Minicell display and products therefrom
DE602006017806D1 (de) * 2005-02-18 2010-12-09 Proximagen Ltd Behandlung von neurodegeneration
EP2385061A3 (en) * 2005-05-10 2012-02-22 Neoloch Aps Neuritogenic peptides
CA2663749A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
BRPI0706540A2 (pt) 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
MX2008012291A (es) * 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
DK2121586T3 (en) 2007-03-09 2017-06-19 Pathologica Llc MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS
DK2201138T3 (en) 2007-10-16 2015-05-18 Ventana Med Syst Inc GRADING, STAGE DETERMINATION AND FORECAST OF CANCER USING osteopontin-C
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
KR20110086757A (ko) 2008-11-20 2011-07-29 메르크 파텐트 게엠베하 암을 치료하기 위해 인테그린 리간드를 사용하는 신규한 치료요법 및 약제
CN102448497A (zh) 2009-05-25 2012-05-09 默克专利有限公司 在癌症治疗中的西仑吉肽的持续给药
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia

Similar Documents

Publication Publication Date Title
JP2014533681A5 (https=)
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
JP2013520405A5 (https=)
JP2020023567A5 (https=)
JP2016512248A5 (https=)
JP2012012418A5 (https=)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
HRP20190982T1 (hr) Peptidi i njihova uporaba
GB2495676A (en) Use of binders for manufacturing storage stable formulations
JP2014169326A5 (https=)
MX346730B (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
JP2015517488A5 (https=)
JP2014050390A5 (https=)
JP2015510393A5 (https=)
JP2014167010A5 (https=)
JP2014508138A5 (https=)
JP2017507142A5 (https=)
AR069211A1 (es) Derivados de acidos de 1,2,4-oxadiazol ciclobutanoamino carboxilicos, una composicion farmaceutica, proceso de preparacion del compuesto y su uso para preparar medicamentos
FI3065763T4 (fi) Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
JP2014532722A5 (https=)
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
JP2018521086A5 (https=)